-
EHA 2026 Clinical Excellence Awardee Prof. Josep Maria Ribera: Crossing 40 Years to Open a New Era of Precision Treatment for Acute Lymphoblastic Leukemia
At the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Josep Maria Ribera from the Josep Carreras Leukemia Research Institute and the Catalan Institute of Oncology (ICO) was honored with the “EHA Clinical Excellence Award.” In his subsequent award lecture, Prof. Ribera systematically reviewed the successful transformation of Acute Lymphoblastic Leukemia (ALL) from a “diagnostic…
-
Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies
At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has…
-
EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles
In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled “From gene profiles to therapy profiles – a quarter century of molecular hematology.” Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis…
-
Second-generation vs. First-generation FLT3 Inhibitors: PASHA Study Reveals Clinical Benefits and Challenges of Gilteritinib Combined with First-line Intensive Chemotherapy
In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment,…
-
83% EFS Reaches New High! AIEOP-BFM Study Confirms Replacing Chemotherapy with Blinatumomab Significantly Improves Prognosis in High-Risk B-ALL Pediatric Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Martin Schrappe, on behalf of the AIEOP-BFM consortium, announced the latest analysis data from the Phase III randomized controlled clinical trial AIEOP-BFM ALL 2017. This study aimed to explore the clinical benefits of using the bispecific antibody Blinatumomab to completely replace two cycles of high-intensity…
-
As of the data analysis date, a total of 17 patients were enrolled. The median age was 63 years, the median number of prior treatment lines was 4, and 65% of patients had received at least one prior allogeneic hematopoietic stem cell transplant.
Although progress has been made in the treatment of Acute Myeloid Leukemia (AML) over the past few decades, clinical options remain very limited for patients with relapsed/refractory (R/R) disease. Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary breakthroughs in B-cell malignancies; however, its application in the field of AML has faced significant challenges due…
-
Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization
In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing…
-
New Breakthrough in Fixed-Duration Regimens: PVR Regimen Reduces Risk of Progression by 45% Compared to VR in R/R CLL Patients
At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab…
Connecting Medical Expertise through Media